Literature DB >> 16223940

Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.

José Antonio Morales-Molina1, Javier Mateu-de Antonio, Mónica Marín-Casino, Santiago Grau.   

Abstract

OBJECTIVES: To study the characteristics of the linezolid-associated serotonin syndrome cases.
METHODS: Database search for linezolid-associated serotonin syndrome.
RESULTS: Twelve cases were found. The mean age of patients was 52.8 years. All patients received linezolid concomitantly with selective serotonin re-uptake inhibitor drugs (SSRID). The onset of syndrome was 9.5 days after linezolid introduction and was directly correlated to patients' age (P = 0.024). The symptoms resolved in 2.9 days. Citalopram was associated with a delayed resolution (P = 0.018). A trend was observed towards longer resolution time the longer the half-life of the interacting drug (P = 0.096).
CONCLUSIONS: Patients are at risk when receiving SSRID concomitant with linezolid. The syndrome onset could be delayed in older patients. The resolution could be delayed when citalopram is involved in the syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16223940     DOI: 10.1093/jac/dki368

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

2.  Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.

Authors:  R R Ramsay; C Dunford; P K Gillman
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

3.  Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases.

Authors:  Ursula Werneke; Fariba Jamshidi; David M Taylor; Michael Ott
Journal:  BMC Neurol       Date:  2016-07-12       Impact factor: 2.474

Review 4.  Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections.

Authors:  Olivia Ferrández; Olatz Urbina; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2016-12-22       Impact factor: 4.162

5.  Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis.

Authors:  Milo Gatti; Emanuel Raschi; Fabrizio De Ponti
Journal:  Eur J Clin Pharmacol       Date:  2020-09-08       Impact factor: 2.953

6.  Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs.

Authors:  Eva Benavent; Laura Morata; Francesc Escrihuela-Vidal; Esteban Alberto Reynaga; Laura Soldevila; Laia Albiach; Maria Luisa Pedro-Botet; Ariadna Padullés; Alex Soriano; Oscar Murillo
Journal:  Antibiotics (Basel)       Date:  2021-01-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.